![Storaktionærmeddelse](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Storaktionærmeddelse
July 15, 2016 09:55 ET
|
Zealand Pharma A/S
København, 15. juli 2016 – Zealand meddeleler, at selskabet har modtaget en storaktionærmeddelelse fra Sunstone LSV Management A/S, Lautrupsgade 7, 5., 2100 København Ø (CVR-nr. 33 85 91 98)....
![Major shareholder an](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Major shareholder announcement
July 15, 2016 09:55 ET
|
Zealand Pharma A/S
Copenhagen, 15 July 2016 – Zealand informs that the company has received a major shareholder announcement from Sunstone LSV Management A/S, Lautrupsgade 7, 5., 2100 Copenhagen (CVR no. 33 85 91 98)....
![Zealand tildeler war](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand tildeler warrants under medarbejder-warrantprogram
July 15, 2016 05:23 ET
|
Zealand Pharma A/S
København, 15. juli 2016 - Zealand meddeler at have tildelt warrants til ét medlem af selskabets ledelse. Tildelingen af warrants sker under warrantprogrammet, der er dækket af bemyndigelsen i § 8.4...
![Zealand grants new w](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand grants new warrants under employee warrant program
July 15, 2016 05:23 ET
|
Zealand Pharma A/S
Copenhagen, 15 July 2016 - Zealand announces the grant of warrants to a member of the company’s senior management. The warrants are granted under the warrant program covered by the authority...
![Zealand meddeler det](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand meddeler det samlede antal aktier og stemmerettigheder i selskabet pr. 30. juni 2016
June 30, 2016 06:14 ET
|
Zealand Pharma A/S
København, 30. juni 2016 – I henhold til § 6 i Bekendtgørelse om udsteders oplysningsforpligtelser udsender Zealand meddelelser med information om det samlede antal aktier og stemmerettigheder i...
![Zealand announces th](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand announces the total number of shares and voting rights in the company as of 30 June 2016
June 30, 2016 06:14 ET
|
Zealand Pharma A/S
Copenhagen, 30 June 2016 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand issues announcements to inform of the total number of shares and...
![Zealand increases it](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand increases its share capital as a consequence of exercise of employee warrants
June 16, 2016 06:52 ET
|
Zealand Pharma A/S
Copenhagen, 16 June 2016 – Zealand has increased its share capital with nominal DKK 41,269 divided into 41,269 new shares with a nominal value of DKK 1 each. The increase is a consequence of the...
![Zealand forhøjer akt](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Zealand forhøjer aktiekapitalen som følge af udnyttelse af medarbejderwarrants
June 16, 2016 06:52 ET
|
Zealand Pharma A/S
København, 16. juni 2016 – Zealand meddeler at have forhøjet sin aktiekapital med nominelt 41.269 kr. fordelt på 41.269 nye aktier à nominelt 1 kr. Forhøjelsen er sket som følge af, at der er sket...
![Positive results fro](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Positive results from pivotal Phase III clinical trials with iGlarLixi presented at the American Diabetes Association 76th Scientific Sessions
June 12, 2016 15:46 ET
|
Zealand Pharma A/S
Type 2 diabetes patients treated with iGlarLixi (formerly LixiLan) had significantly greater reductions in blood glucose (HbA1c) versus treatment with either lixisenatide or Lantus®...
![Positive resultater](/news-release/logo/356649/0/356649.jpg?lastModified=12%2F09%2F2016%2022%3A41%3A25&size=2)
Positive resultater fra kliniske fase III-studier med iGlarLixi er blevet præsenteret på den 76. amerikanske diabeteskongres (ADA)
June 12, 2016 15:46 ET
|
Zealand Pharma A/S
Type 2-diabetikere behandlet med iGlarLixi (tidligere benævnt LixiLan), opnåede en signifikant større sænkning af deres langtidsblodsukker (HBA1c) i forhold til behandling med enten lixisenatid...